Novavax, Inc. (NVAX )

Currency in USD Disclaimer

$7.28 -$0.19 (-2.54%)

Open 04/24/2025

Day's Range

$7.28

$7.49

52 wk Range

$3.9

$23.86

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Symbol NVAX
Company Novavax, Inc.
Price $7.28
Changes Percentage -2.54
Change -0.19
Day Low $7.28
Day High $7.49
Year High $23.86
Year Low $3.9
Market Cap $1,201,504,680
Price Avg 50 EMA (D) $7.3
Price Avg 200 EMA (D) $9.97
Exchange NASDAQ
Volume 14,721,119
Average Volume 4,781,536
Open $7.49
Previous Close $7.47
EPS -1.23
PE -6.07
Earnings Announcement 2025-05-08 12:30:00
Shares Outstanding $160,844,000

Company brief: NOVAVAX, INC. (NVAX )

Sector Healthcare
Industry Biotechnology
CEO Mr. John Charles Jacobs M.B.A.
Website https://www.novavax.com
Headquarters US
Employees (FY) N/A
Founded 12-05-1995
ISIN US6700024010

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.